CALLE DOCTOR FLEMING, 51 | 28036 MADRID, SPAIN
+34 91 3459395
info@oxonepi.com

RAPID
Retrospective Analyses of Potential Interventions and Determinants for COVID-19

“OXON leads international collaborative programme to evaluate non-randomised comparative studies of treatments for COVID-19 and prognostic factors”

BACKGROUND

The new coronavirus pandemic is an international emergency that is causing severe medical burden.

Covid-19 is the new corona virus-induced disease and SARS-CoV-2 is the RNA coronavirus, which is also called Covid-19 virus by World Health Organization (WHO). The Covid-19 virus is highly contagious and causes high morbidity – with severe cases requiring hospitalisation and ventilatory support which can overwhelm national health systems – and significant mortality and for which there is no demonstrated effective vaccine or treatment.
Hence, many repurposed drugs are being tested for their usefulness in COVID-19.

OXON is working with an international team of academics, and clinicians who treat COVID-19 patients, to help provide reliable evidence to make decisions about pharmacological interventions in hospitalized COVID-19 patients.

OVERVIEW OF THE PROGRAMME

OXON’s COVID-19 Ongoing Projects

Retrospective Cohort Analysis: Treatments for COVID-19

This is a retrospective study to evaluate the clinical effectiveness and safety of treatments for Covid-19 hospitalised patients and to determine prognostic factors in Spain.

Meta-analysis of non-randomised treatment studies

This is a ´real-time´ systematic review and meta-analysis of non-randomised comparative studies of treatments for hospitalised patients with COVID-19.
To compare in-hospital all-cause mortality in patients managed with standard care and various treatments for COVID-19 in published non-randomised comparative studies.

Contact our core team